11:55:37 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-02-27 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-10 Ordinarie utdelning REDS 0.00 SEK
2023-05-09 Kvartalsrapport 2023-Q1
2023-05-09 Årsstämma 2023
2023-02-27 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-03 Ordinarie utdelning REDS 0.00 SEK
2022-05-02 Årsstämma 2022
2022-05-02 Kvartalsrapport 2022-Q1
2022-02-28 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-12 Årsstämma 2021
2021-05-05 Ordinarie utdelning REDS 0.00 SEK
2021-05-03 Kvartalsrapport 2021-Q1
2021-04-19 Extra Bolagsstämma 2021
2021-02-28 Bokslutskommuniké 2020
2020-12-18 Extra Bolagsstämma 2020
2020-11-09 Kvartalsrapport 2020-Q3
2020-08-24 Kvartalsrapport 2020-Q2
2020-06-23 Ordinarie utdelning REDS 0.00 SEK
2020-06-22 Årsstämma 2020
2020-05-04 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2019-11-18 Kvartalsrapport 2019-Q3
2019-08-26 Kvartalsrapport 2019-Q2
2019-05-07 Ordinarie utdelning REDS 0.00 SEK
2019-05-06 Kvartalsrapport 2019-Q1
2019-05-06 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-08-27 Kvartalsrapport 2018-Q2
2018-05-08 Ordinarie utdelning REDS 0.00 SEK
2018-05-07 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-09-25 Extra Bolagsstämma 2017
2017-08-28 Kvartalsrapport 2017-Q2
2017-04-06 Ordinarie utdelning REDS 0.00 SEK
2017-04-05 Årsstämma 2017
2017-02-22 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-09 Kvartalsrapport 2016-Q1
2016-05-09 Årsstämma 2016
2016-02-23 Ordinarie utdelning REDS 0.00 SEK
2016-02-22 Bokslutskommuniké 2015
2015-11-27 Kvartalsrapport 2015-Q3


Redsense Medical är ett medicinteknikbolag som är specialiserade inom utvecklingen av blodläckage-alarm. Bolagets produkt fungerar som en sensor baserad på fiberteknik som snabbare skall upptäcka blodförlust, samt larma och rapportera till olika larmenheter. Utöver huvudverksamheten erbjuds träning och utbildning inom affärsområdet. Bolaget grundades år 2006 och har sitt huvudkontor i Halmstad.
2022-03-23 09:57:36

Redsense Medical announces today that the UK Medicines & Healthcare Products Regulatory Agency (MHRA) has issued a new dialysis guidance, in which venous needle dislodgement (VND) is explicitly acknowledged as an important issue that should be addressed to ensure the safety of patients. Currently, Redsense offers the only standalone blood loss monitor registered with the MHRA for use on the UK market.

The MHRA is the UK executive agency responsible for ensuring the safety and regulatory compliance of medicines and medical devices in the UK market. On March 8, 2022, the MHRA published an updated guidance relating to dialysis care in the United Kingdom, aimed at healthcare professionals and dialysis patients.

The new guidance (https://www.gov.uk/government/publications/dialysis-guidance/dialysis-guidance), which was developed in cooperation with the UK Kidney Patient Safety Committee (KPSC), summarizes the known safety issues with dialysis and other renal therapies and recommends various measures that should be implemented during treatment to minimize or prevent adverse events.

The guidance emphasizes the risk of severe blood loss from VND incidents and states that both staff and patients should be educatedon the possible consequences and implement actions to counter the risk. It goes on to underline that the HD machine itself can not be relied upon to detect VND, and that patients must be individually assessed. High risk patients are recommended to use external alarm devices intended for VND monitoring.

"The MHRA's acknowledgement that venous needle dislodgement is a serious risk that requires specific monitoring is an important step that will protect and benefit the UK dialysis patients,"says Patrik Byhmer, CEO of Redsense Medical AB: "As previously disclosed, the Redsense Alarm, our well-established VND monitoring device, is already registered with the MHRA and will therefore have full access to the UK market even when the country ceases to accept the European CE marking next year."

About venous needle dislodgement (VND) and Redsense

During hemodialysis, vascular access points are opened to the patient's bloodstream to draw and return blood for extracorporeal purification. Sometimes, the venous needle accidentally comes out of the access point - for example if the needle is not secured correctly, or if the bloodline is pulled - which immediately results in blood loss and quickly poses a major risk for the patient. The Redsense Alarm is an established patient safety device that uses fiber-optic technology and light to continuously monitor for blood leakage and alert the nurses' and patient's attention if VND occurs.